ABSTRACT
Polyhydroxybutyrate (PHB), co-polyesters of 3-hydroxybutyrate and 3-hydroxyhexanoate (PHBHHx), and polylactic acid (PLA) were used to prepare nanoparticles with average sizes of 160, 250 and 150 nm, respectively. A lipid-soluble colorant, rhodamine B isothiocyanate (RBITC), was employed to study drug-release behaviors from these nanoparticles. A high RBITC drug-loading efficiency of over 75% was achieved with all PHA nanoparticles prepared. Macrophage endocytosis led to an intracellular RBITC drug sustained release over a period of at least 20 days for PHB and PHBHHx nanoparticles, while PLA nanoparticles and free drug lasted only 15 days and a week, respectively. Polymer properties and particle sizes showed little effect on drug-release behavior. This study showed for the first time that PHB and PHBHHx can be used effectively to achieve intracellular controlled drug releases.
Subject(s)
Delayed-Action Preparations/chemistry , Nanoparticles/chemistry , Polyhydroxyalkanoates/chemistry , Rhodamines/administration & dosage , Animals , Cells, Cultured , Endocytosis , Hydroxybutyrates/chemistry , Lactic Acid/chemistry , Macrophages/cytology , Male , Mice , Mice, Inbred BALB C , Polyesters/chemistry , Polymers/chemistryABSTRACT
Learning and memory requires energy-demanding cellular processes and can be enhanced when the brain is supplemented with metabolic substrates. In this study, we found that neuroglial cell metabolic activity was significantly elevated when cultured in the presence of polyhydroxybutyrate (PHB) degradation product 3-hydroxybutyrate (3-HB) and derivatives. We demonstrated that the receptor for 3-HB, namely, protein upregulated in macrophages by IFN-gamma (PUMA-G), was expressed in brain and upregulated in mice treated with 3-hydroxybutyrate methyl ester (3-HBME). We also affirmed increased expression of connexin 36 protein and phosphorylated ERK2 (extracellular signal-regulated kinase 2) in brain tissues following 3-HBME treatment, although these differences were not statistically significant. Mice treated with 3-HBME performed significantly (p<0.05) better in the Morris water maze than either the negative controls (no treatment) or positive controls (acetyl-l-carnitine treatment). Moreover, we found that 3-HBME enhanced gap junctional intercellular communication between neurons. Thus, 3-HB and derivatives enhance learning and memory, possibly through a signaling pathway requiring PUMA-G that increases protein synthesis and gap junctional intercellular communication.
Subject(s)
Hydroxybutyrates/pharmacology , Memory/drug effects , Acetylcarnitine/pharmacology , Animals , Cell Communication/drug effects , Cells, Cultured , Connexins/metabolism , Gap Junctions/drug effects , Gap Junctions/metabolism , Hippocampus/drug effects , Hippocampus/enzymology , Maze Learning/drug effects , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinase 1/metabolism , Neuroglia/drug effects , Neuroglia/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism , Receptors, Nicotinic/genetics , Receptors, Nicotinic/metabolism , Transcription, Genetic/drug effects , Gap Junction delta-2 ProteinABSTRACT
Polyhydroxyalkanoates (PHA) is a family of intracellular biopolyesters produced by many bacteria. PHA granule binding protein PhaP is able to bind to hydrophobic polymers via strong hydrophobic interaction. A receptor-mediated drug delivery system was developed in this study based on PhaP. The system consists of PHA nanoparticles, PhaP and polypeptide or protein ligands fused to PhaP. The PHA nanoparticles were used to package mostly hydrophobic drugs; PhaP fused with ligands produced by over-expression of their corresponding genes in Pichia pastoris, or E. coli was able to attach to hydrophobic PHA nanoparticle. At the end, the ligands were able to pull the PhaP-PHA nanoparticles to the targeted cells with receptors recognized by the ligands. It was found in this study that the receptor-mediated drug specific delivery system ligand-PhaP-PHA nanoparticles were taken up by macrophages, hepatocellular carcinoma cell BEL7402 in vitro and liver, hepatocellular carcinoma cells in vivo, respectively, when the ligands were mannosylated human alpha1-acid glycoprotein (hAGP) and human epidermal growth factor (hEGF), respectively, which were able to bind to receptors of macrophages or hepatocellular carcinoma cells. The nanoparticle system was clearly visible in the targeted cells and organs (liver or tumor) under fluorescence microscopy when rhodamine B isothiocyanate (RBITC) was used as a delivery model drug due to the specific targeting effect created by specific ligand and receptor binding. The delivery system of hEGF-PhaP-nanoparticles carrying RBITC was found to be endocytosed by the tumor cells in tumorous model mice. Thus, the ligand-PhaP-PHA specific drug delivery system was proven effective both in vitro and in vivo.